18+ • For Research & Educational Purposes Only • Not Medical Advice  Disclaimer
Peptide Wiki
Fat Loss & GH OptimizationPhase 2

AOD-9604

Modified C-terminal fragment of human growth hormone targeting fat metabolism without the insulin resistance or growth effects of full HGH

Research Reality Check

Worth WatchingThere is a real signal, but it is not settled.
ClaimSome people claim AOD-9604 has clear value for fat loss & gh optimization research.
RealityThere is a real research signal, but important questions remain.
Bottom LineUse the evidence score, sources, and safety notes before taking any claim seriously.
Why People Believe ThisSimple explanations and user stories can sound more certain than the research is.
Watch Out For
Guaranteed resultsExact protocols presented as provenAnecdotes used as proof
234Discussions
2Citations

Evidence Dossier

79Evidence

Phase 2

Evidence score reflects source depth, citations, and research maturity. It is not a medical recommendation.

2Citations
234Discussions
Start Here

AOD-9604 at a glance

A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.

Evidence score79Phase 2 human research
Primary routeSubcutaneous InjectionRoute availability varies by context
Safety depthLimited dataReview safety notes before making assumptions
Community questions234Related discussions and experiences

AOD-9604 is a synthetic peptide comprising amino acids 176-191 of the C-terminal region of human growth hormone, with a tyrosine residue added at the N-terminus for stability. It was developed by Metabolic Pharmaceuticals to isolate HGH's lipolytic (fat-burning) properties from its anabolic and insulin-desensitizing effects.

How It Works

In animal studies, AOD-9604 stimulated fat breakdown (lipolysis) and inhibited fat formation (lipogenesis) in adipose tissue by mimicking the way HGH regulates fat metabolism - without binding to the IGF-1 receptor or affecting glucose metabolism. This dissociation from the IGF-1 pathway means AOD-9604 does not promote cell growth, cause insulin resistance, or produce the side effects associated with recombinant HGH.

AOD-9604 completed Phase II clinical trials for obesity but failed to meet primary endpoints in Phase III (METAOD006 trial) for mean weight loss. Despite this, it has been granted GRAS (Generally Recognized As Safe) status by the FDA for use as a food additive and is widely used in research and off-label clinical settings for fat loss and cartilage repair (a secondary finding from animal studies).

Key Benefits

✓
Fat lipolysis without insulin resistance
✓
No growth-promoting effects (IGF-1 independent)
✓
Potential cartilage and bone repair
✓
Excellent safety profile

Saves this peptide to your Watchlist and helps you find new research, news, and questions later.

Quick Dosing Reference
Dose Range300-500mcg
FrequencyOnce daily
RouteSubQ injection
Experience LevelBeginner